ACR 2016

One-Year Efficacy of Ixekizumab in Psoriatic Arthritis

WASHINGTON, DC — Treatment of psoriatic arthritis (PsA) with ixekizumab (IXE)—an IgG4 monoclonal antibody—significantly improves arthritis, dactylitis and enthesitis at 52-weeks, according to research presented at the 2016 American College of Rheumatology Annual Meeting. Philip J Mease, MD, at the Swedish Medical Center and the University of Washington, and colleagues conducted a phase 3 study…

Safety of ADA in Pediatric Polyarticular JIA, ERA

WASHINGTON, DC — There was no change in safety profile for adalimumab in pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA), enthesitis-related arthritis (ERA), psoriasis (Ps), and Crohn’s disease (CD), a recent analysis showed. The research was presented at the American College of Rheumatology (ACR) 2016 Annual Meeting. Gerd Horneff, MD, from the Asklepios Kliniken GmbH…

Loss of Pulmonary Function Worse in RA-ILD With UIP vs NSIP

WASHINGTON, DC — While it is established that interstitial lung disease (ILD) is linked with higher morbidity in patients with rheumatoid arthritis (RA), insights into the long-term progression of pulmonary impairment in such patients are lacking. Findings to be presented at the 2016 annual meeting of the American College of Rheumatology (ACR) will offer some initial…

Next post in ACR 2016 Coverage